Bedrijfstakpensioenfonds Voor DE Media PNO maintained its stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, Holdings Channel reports. The fund owned 212,100 shares of the company’s stock at the end of the first quarter. Eli Lilly and Company makes up approximately 2.1% of Bedrijfstakpensioenfonds Voor DE Media PNO’s investment portfolio, making the stock its 17th largest position. Bedrijfstakpensioenfonds Voor DE Media PNO’s holdings in Eli Lilly and Company were worth $17,840,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. ETRADE Capital Management LLC increased its stake in shares of Eli Lilly and Company by 37.7% in the third quarter. ETRADE Capital Management LLC now owns 12,904 shares of the company’s stock valued at $1,036,000 after buying an additional 3,531 shares during the period. Arthur M. Cohen & Associates LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $3,485,000. Norway Savings Bank bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $260,000. Hodges Capital Management Inc. increased its stake in shares of Eli Lilly and Company by 11.4% in the fourth quarter. Hodges Capital Management Inc. now owns 17,413 shares of the company’s stock valued at $1,281,000 after buying an additional 1,784 shares during the period. Finally, Wechter Feldman Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $935,000. Hedge funds and other institutional investors own 75.44% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) opened at 81.88 on Friday. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The company has a market capitalization of $86.49 billion, a price-to-earnings ratio of 39.59 and a beta of 0.36. The stock’s 50 day moving average price is $80.08 and its 200 day moving average price is $78.91.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. The company had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.22 billion. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.83 earnings per share. Equities research analysts anticipate that Eli Lilly and Company will post $4.12 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 9th. Investors of record on Monday, May 15th were given a $0.52 dividend. The ex-dividend date of this dividend was Thursday, May 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. Eli Lilly and Company’s dividend payout ratio is currently 100.48%.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.financial-market-news.com/2017/06/17/bedrijfstakpensioenfonds-voor-de-media-pno-holds-position-in-eli-lilly-and-company-lly.html.

A number of research analysts have issued reports on LLY shares. Piper Jaffray Companies restated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and Company in a research note on Monday, April 17th. Credit Suisse Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 21st. Argus downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and upped their price objective for the company from $64.18 to $81.00 in a research note on Thursday, April 27th. They noted that the move was a valuation call. Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 price objective on shares of Eli Lilly and Company in a research note on Sunday, May 21st. Finally, Jefferies Group LLC restated a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and Company in a research note on Monday, June 5th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $87.59.

In related news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold 259,733 shares of company stock worth $21,829,137 over the last quarter. 0.20% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.